Fundraising Fox

Dualitas Therapeutics

South San Francisco, US · Founded 2023 · Delaware corporation · 5 known investors

dualitastx.com

Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations. Its pipeline targets autoimmune, allergic, and other immune and inflammatory diseases, with lead candidate DTX-102 for rheumatoid arthritis in IND-enabling studies.

BiotechDeep Tech

Founders & leadership

FHForbes Huang
Forbes HuangCo-Founder, Chief Operating Officer & Chief Business Officer
GLGreg Lazar
Greg LazarCo-Founder & Chief Scientific Officer
RM
Richard MurrayExecutive
KD
Karim DabbaghChief Executive Officer, Board Member

Board

AL
Alicia LeveyBoard director
MR
Michael RossBoard directorSenior Partner at Dementia Discovery Fund
NW
Neil WeirBoard directorVenture Partner at Dementia Discovery Fund
MM
Mark McDadeBoard director
NT
Nikola TrbovicBoard directorManaging Partner at Dementia Discovery Fund
TH
Thomas HudsonBoard director

Investors · 5

Reported raises · per SEC filings

Form D private placements

$32.6M disclosed across 1 round · 2025

$32.6MraisedNov 2025 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas HudsonDirector
  • Forbes HuangExecutive Officer
  • Alicia LeveyDirector
  • Michael RossDirector
  • Greg LazarExecutive Officer
  • Neil WeirDirector
  • Mark McDadeDirector
  • Richard MurrayExecutive Officer, Director
  • Nikola TrbovicDirector
Offering amount
$66.6M
Amount sold
$32.6M
First sale
Jul 2025
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap
Immunitas Therapeutics10 shared keywordsImmunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies. The company is building on research from academic institutions including Dana Farber Cancer Institute and MIT.
Abilitatx6 shared keywordsAbilita Bio is a biotechnology company focused on drug discovery targeting membrane proteins, with a research team working in areas such as oncology, pharmacology, and antibody development. The company operates a laboratory-based research program led by scientists across multiple disciplines.
Fortis Life Sciences5 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Cabaletta Bio4 shared keywordsCabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases. Its CABA platform and lead CARTA program center on rese-cel, an investigational CD19-CAR T cell therapy being evaluated in trials across rheumatology, neurology, and dermatology.
Alloy4 shared keywordsAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.

Companies competing with Dualitas Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Dualitas Therapeutics do?
Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations. Its pipeline targets autoimmune, allergic, and other immune and inflammatory diseases, with lead candidate DTX-102 for rheumatoid arthritis in IND-enabling studies.
Who are Dualitas Therapeutics's investors?
Dualitas Therapeutics's investors include Qiming Venture Partners, SV Health Investors, Versant Ventures, Dementia Discovery Fund, Qiming Healthcare.
How much funding has Dualitas Therapeutics raised?
Dualitas Therapeutics has disclosed $32.6M raised across 1 round.
Where is Dualitas Therapeutics headquartered?
Dualitas Therapeutics is headquartered in South San Francisco, US.